DIRECT ACTING ANTIVIRALS (DAA) IN CHRONIC HEPATITIS C INFECTION WITH LIVER CIRRHOSIS

Dr. Maryam Basharat, Dr. Mina Mishal, Dr. Mujahid Abbas

1MBBS; King Edward Medical University Lahore, Pakistan., 2MBBS; King Edward Medical University Lahore, Pakistan., 3MD; S. Tentishev Asian Medical Institute, Kyrgyzstan.

Abstract:
Chronic hepatitis C virus (HCV) infection could ultimately trigger liver cirrhosis (LC), an ailment corresponding by getting a high risk of liver failure and hepatocellular carcinoma. Despite the fact that interferon (IFN)-based therapy has produced considerable advantages to the handling of HCV-infected patients, this particular treatment has restrictions for LC patients with regards to qualification, tolerability, reasonably minimal and higher rates of sustained virological response (SVR), and serious adverse events.

The development of Direct-acting antiviral (DAA) therapy could customize the consequence of HCV infection through the vast majority of patients. Regrettably, the chronic nature of HCV infection means that many patients requiring direct acting antiviral (DAA) therapy have already developed compensated cirrhosis. As mentioned, treatment with recently evolved direct-acting antiviral agents (DAAs) can overcome these limitations in IFN-based therapy.

Recently, in the phase three trials have revealed that DAA therapy produced high SVR rates (more than 90% for genotype 1; 80% to 90% for genotype 2; 60% to 70% for genotype 3) for compensated LC patients, with high tolerability and relatively low rates of serious adverse events. Furthermore, trials have suggested that DAA therapy can be used for the treatment of decompensated LC patients as well as pre-transplant and post-transplant LC patients. In this article, we review the current status of DAA therapy for HCV-related LC patients.

Keywords: Liver cirrhosis; Hepatitis C virus; Direct-acting antiviral agents.

Corresponding author:
Dr. Maryam Basharat,
MBBS; King Edward Medical University Lahore, Pakistan.
INTRODUCTION:
Chronic hepatitis C virus (HCV) infection is epidemic, with more than 185 million individuals infected around the world. Several HCV genotypes have already been observed thus far, and HCV genotype 1 stands out as the most predominant (46.2%) on the planet, followed by genotypes 3 (30.1%), 2 (9.1%), 4 (8.3%), 6 (5.4%), and 5 (0.8%). Chronic HCV infection commonly produces chronic liver inflammation, which could ultimately produce liver cirrhosis (LC), an ailment connected with a perilous of liver failure and hepatocellular carcinoma (HCC). An epidemiological research predicted that all over the world in 2012, 211,000 and 155,000 HCV-infected individuals died as a consequence of LC and HCC, respectively (Bruno, 2013).

Therefore, LC is an essential stage of HCV-associated liver disease. Antiviral therapy obviously performs an important role through the administration of HCV-related liver disease. In this study, there is initially a review interferon (IFN)-based therapy and reveal dilemmas in the use of this treatment for LC patients. Secondly, there is a description of IFN-free, oral direct-acting antiviral agent (DAA) therapy and negotiate the high potential that this newly developed antiviral therapy will radically alter the management of HCV-related LC patients (Boccaccio and Bruno, 2013).

The authentic therapy option in prolonged HCV infection was interferon-based regimens. Interferon-based regimens had been once the forestay of remedy; nevertheless it has restricted advantages as part of the capability to consistently trigger a sustained virological response (SVR) in chronic HCV at high adequate rates to be a credible solution for HCV. As a consequence of the infectious and chronic nature of hepatitis C, a progressively prosperous therapy than interferon-based therapy was required to lessen the worldwide burden of disease. Along with its ineffectiveness, interferon-based regimens had several side effects. The side effects tend to be serious and debilitating, including bone marrow depression, neuropsychiatric symptoms, and flu-like symptoms. These types of side effects probably helped with decreased patient attachment to interferon therapy (Halfon and Sarrazin, 2016). Only in Africa, 13.1 million in the Americas, 21.3 million in the eastern Mediterranean, 8.9 million in Europe, 32.3 million in Asia (includes India, Pakistan and Indonesia), and 62.2 million in the western Pacific (includes China and Japan). In the United States the incidence of HCV antibody is 1.8%, indicating that 3.9 million Americans have been exposed. Seventy-four per cent of those with positive HCV antibody also test positive for HCV RNA, yielding an estimated 2.7 million Americans with active infection (Halfon and Sarrazin, 2016).

HCV is a blood-borne virus and will result in chronic infection in 55–85% of patients. Once the infection is chronic, patients are unlikely to have spontaneous resolution of their infection and are thus at risk of fibrosis, cirrhosis, and hepatocellular carcinoma. Approximately 20–30% of patients with chronic HCV infection will develop cirrhosis. There are numerous host factors in determining whether or not there will be a chronic infection, including IL-28B polymorphisms which may be associated with spontaneous resolution of the infection. The development of cirrhosis at a cellular level is due to the virus inducing CD8+ T cell inflammation and necrosis, which is then followed by eventual healing via fibro-genesis pathways. This cycle of insult and healing can result in cirrhosis after 10–20 years of viral hepatitis (Jensen and Pol, 2017). Cirrhosis is a significant cause of detriment in the chronic HCV infection and ultimately can lead to the end stages of HCV infection, including decompensating, hepatocellular carcinoma (HCC), death, or the need for transplantation. Decompensated cirrhotic patients HCV develop encephalopathy, ascites, or variceal bleed. Both variceal hemorrhage and HCC represent the fatal consequences of chronic HCV and cirrhosis. Numerous studies done on DAAs and prevention of hepatocellular carcinoma indicate that DAA therapy does ultimately decrease the overall risk of HCC (Halfon and Sarrazin, 2016).

How sick are patients who have experienced decompensating? Examination of Model for End-Stage Liver Disease (MELD) scores in patients on the US waiting list for liver transplantation indicates that approximately 90% of HCV patients listed at active status have MELD scores of 18 or less. The range of biochemical tests between MELD 6 and 18 spans the normal to moderately abnormal spectrum. While one of the most important goals of treating HCV is to prevent cirrhosis; a significant portion of HCV patients already have existing cirrhosis in need of DAA therapy. Furthermore, these patients are more likely to have DAA treatment failure versus their non-cirrhotic counterparts. This makes DAA

CHRONIC HEPATITIS C AND COMPENSATED CIRRHOSIS:
World Health Organization data demonstrates there are 169.7 million instances of hepatitis C virus (HCV) infection around the world with 31.9 million...
therapy of paramount significance for clinicians, in both preventing HCV cirrhosis and emphasizing the importance of selecting an appropriate DAA regimen in HCV patients with compensated cirrhosis (Jensen and Pol, 2017).

**DAA (DIRECT-ACTING ANTIVIRAL AGENTS):**

DAAAs had been initially licensed by the Food and Drug Administration (FDA) in 2011 and had been applied primarily together with the existing criterion of care interferon-based regimens. DAAAs might be categorized into 4 different groups; protease inhibitors, polymerase inhibitors, NS5B inhibitors, and NS5A inhibit. The major procedure of DAAAs is always to exclusively restrict the life cycle reproduction of HCV virus. It is also specified techniques of level of resistance which the HCV virus may formulate, which is important to contemplate the opportunity of resistance when beginning HCV therapy. Generally there are extensive regimens presented regarding DAAAs (Halfon and Sarrazin, 2016). The American Association for the Study of Liver disease (AASLD) have produced HCV recommendations to support in choosing a specific DAA regimen predicated on specifics such as the genotype of HCV infection, treatment naïve status, existing compensated cirrhosis, decompensated cirrhosis, and co-infection with HIV as mentioned in below Table 1.

| Genotype     | Drug                        | Treatment duration (weeks) |
|--------------|-----------------------------|----------------------------|
| Genotype 1   | Elbasvir/Grazoprevir         | 12                         |
|              | Glecaprevir/Pibrentasvir     | 12                         |
| Genotype 2   | Ledipasvir/Sofosbuvir        | 12                         |
|              | Sofosbuvir/Velpatasvir       | 12                         |
| Genotype 3   | Glecaprevir/Pibrentasvir     | 12                         |
|              | Sofosbuvir/Velpatasvir       | 12                         |
| Genotype 4   | Elbasvir/Grazoprevir         | 12                         |
|              | Glecaprevir/Pibrentasvir     | 12                         |
|              | Ledipasvir/Sofosbuvir        | 12                         |
|              | Sofosbuvir/Velpatasvir       | 12                         |
| Genotype 5/6 | Glecaprevir/Pibrentasvir     | 12                         |
|              | Ledipasvir/Sofosbuvir        | 12                         |
|              | Sofosbuvir/Velpatasvir       | 12                         |

**Table 1.**

**DAA regimen for each HCV major genotype in the treatment of patients with compensated cirrhosis, according to current AASLD guidelines.**

Source: (Halfon and Sarrazin, 2016)

Successful DAA therapy is defined as a sustained virologic remission at 12 weeks (SVR12) post-treatment in the infected patient. The success of DAA therapy has a lot of variables, which is addressed in the AASLD guidelines. Corroborating an appropriate regimen based on a specific genotype, the presence of existing cirrhosis, HIV co-infection, treatment naivety, and treatment failure is all addressed in the AASLD guidelines. In addition to the factors addressed in the AASLD guidelines, there appear to be some genetic examples influencing SVR in DAA therapy, include IL-28B polymorphisms, low-density lipid receptor genetic variants, vitamin D receptor, and bile salt export pump polymorphisms (Jensen and
ROLE OF DIRECT-ACTING ANTIVIRAL AGENTS WHILE HCV COMBATING:
As mentioned earlier, DAAs come under four leading classes that focus on one or more of these proteins and enzymes so as to prevent the viral organic phenomenon and minimize viral load. As being a class, most are typically well endured; conversely, as their objective is always to promote particular immune responses they can also improve the risk of HBV reactivation. Prior to launching a DAA medication, in addition to procedures, any physician may monitor the HBV activity in addition to for indications that might point to a difficulty with the liver (Jensen and Pol, 2017).

Numerous DAAs are drawn in collaboration collectively or together with other medicines incorporating ribavirin or peginterferon to increase usefulness and SVR rates. DAAs in combination with recommended global health techniques incorporate us together with the probability to minimize HCV as an effective health problem. Systematic information accumulated originating from a treat-all models reveal there exists a cost-effective advantage to dealing with all HCV affected individuals with DAA regimens. Urbanization is an additional one significant element to contemplate as enhanced rates of urbanization might be linked to the risk of HCV. Not all endemic segments with HCV are countries of means, thus it persist the essential while considering the antiviral regimens price and eradicate any economic limitations around specific extensive treatment response (Manoj Kumar et al., 2018).

Some other studies evaluate the cost of HCV treatment mentioned the existing DAA price point seems to remain practical to treat most communities at an intensive degree, equivalent to HIV. These studies also determined that genotype testing remains a significant cost until a consistent pan-genotypic DAA regimen can be developed. The current DAA regimens and guidelines are contingent on knowing the genotype being treated. This is because much of the existing data in the literature shows a particular regimen’s treatment success rates as a function of the genotype being treated (Marcellin, 2017).

HEPATITIS C GENOTYPES:
There are several HCV Virus genotypes. Accordingly, there is a geographical element in HCV genotypes, as a variety of areas around the globe have a different rate of HCV genotypes. The understanding regarding HCV genotyping is considerable, whilst it assists dictate therapy. The existing AASLD recommendations depend basically on genotype when supporting physicians to select a specific DAA regimen. The genotype also produces pre-treatment achievement prospects while deciding on a DAA regimen for the accomplishment of SVR in patients with present compensated cirrhosis. There is a study which recognized that HCV Genotype 1 patient together with cirrhosis have the tendency to higher SVR irrespective of their cirrhosis status, but Genotype 3 patients employ a additional decreased reaction and are consequently a lot more complicated to deal with in present cirrhosis. Ribavirin might be applied as an accessory with DAA regimens to assist achieves SVR in patients with specific characteristics, incorporating the genotype (Manoj Kumar et al., 2018).

DECOMPENSATED CIRRHOSIS AND DAA THERAPY:
Patients having cirrhosis tend to be susceptible to hepatic decompensation, which contains ascites, encephalopathy, spontaneous bacterial peritonitis and variceal bleed. The formation associated with a component signifies enhance impermanence, and decompensation symbolizes an end stage of HCV infection, with patients suffering from a five-year survival rate of 51%. Decompensation also continues to be an independent risk element towards the advancement of HCC. Choosing an excellent DAA therapy in patients with compensated cirrhosis is consequently essential, as it might assist to prevent the morbidity and impermanence connected with decompensated cirrhosis (Marcellin, 2017).

Generally, there are several DAA regimens that demonstrate feature in patients that have decompensated cirrhosis. Before DAAs, interferon-based regimens had been the exclusive alternative, as well as in specific, when speaking about the decompensated population, interferon-based regimens had been both inadequate and defectively accepted. The ALLY-1 study looked at the effects of Daclatasvir/Sofosbuvir along with ribavirin on patients with advanced cirrhosis, including decompensated cirrhosis across 5 of the 6 major HCV genotypes, with genotype 5 being the only one not represented. They noted a high treatment response with Child-Pugh A or B cirrhosis (93%), but once progression to Child-Pugh C cirrhosis occurred, the efficacy of Daclatasvir/Sofosbuvir was significantly diminished with a treatment response of 56% (Marcellin, 2017).

DAA IN HCV AND COMPENSATED CIRRHOSIS:
The Human Immunodeficiency Virus (HIV) and
Hepatitis C (HCV) are simultaneously blood-borne bacterial infections that communicate frequent risk factors pertaining actions of indication. Intravenous drug consumers may be at risk of both bacterial infections, and intravenous drug consumers describe the most prevalent trigger of new HCV infections. Co-infection with HCV and HIV additionally seems to modify the host immune system, with intense explanation of diminished organic killer cells. Clinicians also must exercise caution as there remains a possibility of drug-drug interaction, including hepatotoxicity between Highly Active-Antiretroviral Therapy (HAART) and DAA (Nagral et al., 2017).

CONCLUSION:
DAA (Direct-acting antivirals agents) describe a discovery with the remedy for hepatitis C virus. It’s equipped with the prospective to minimize the international burden of disease triggered by the natural hepatitis C history, incorporating cirrhosis, decompensation, and hepatocellular carcinoma. Additionally, it can minimize the economic burden of liver transplants. The patient’s with established compensated cirrhosis remain at an increased risk of several other difficulties, so it is important to experience an appropriate therapy to assist decrease poor patient effects. There are several possibilities with the emerging DAA and being able to accordingly choose a program will permit for optimum experienced virologic reactions in patients with compensated cirrhosis. The AASLD recommendations supply an exceptional method to assist stipulate a therapy which is designed to each patient and genetic constitution. As more research is collected on this novel therapy, DAA regimens have the potential to improve on its already remarkable efficacy.

REFERENCES:
1. Boccaccio, V. and Bruno, S. (2013). Management of HCV patients with cirrhosis with direct acting antivirals. Liver International, 34, pp.38-45.
2. Bruno, S. (2013). Management of HCV patients with cirrhosis with direct acting antivirals. Liver International, 34, pp.38-45.
3. Halfon, P. and Sarrazin, C. (2016). Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?. Liver International, 32, pp.79-87.
4. Jensen, D. and Pol, S. (2017). IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?. Liver International, 32, pp.74-78.
5. Jones, M. (2018). Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. Journal of Gastrointestinal and Liver Diseases, 27(3).
6. Manoj Kumar, Nayak, S., Gupta, E., Kataria, A. and Sarin, S. (2018). Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. Liver International, 38(12), pp.2137-2148.
7. Marcellin, P. (2017). New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver International, 31, pp.68-77.
8. Nagral, A., Sawant, S., Malde, P., Parikh, P., Nagral, N. and Merchant, R. (2017). Experience With Direct Acting Antivirals (DAA) Agents in Treatment of Chronic Hepatitis C Virus (HCV) Infection in Patients of Thalassemia Major. Journal of Clinical and Experimental Hepatology, 7, pp.S14-S15.
9. P1-094: Immediate direct-acting antiviral therapy (DAA) of recurrent HCV infection after liver transplantation improves post-transplant survival: single center experience (2014-2017). (2018). Journal of Viral Hepatitis, 25, pp.72-72.
10. Sakamoto, N. (2016). 1. New Therapeutic Strategies for Hepatitis C by Direct-acting Antivirals (DAA). Nihon Naika Gakkai Zasshi, 105(3), pp.424-428.